Purinergic Signalling
Receptor cross-talk: haloperidol treatment enhances A2A adenosine receptor functioning in a
transfected cell model
M. Letizia Trincavelli 1#, S. Cuboni1#, M. Catena Dell’Osso 1, R. Maggio 2, K-N. Klotz 3, F.
Novi 4, A. Panighini 1, S. Daniele 1, C. Martini1*
1Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology. University of Pisa.
56126 Pisa, Italy. 2 Department of Experimental Medicine, University of L'Aquila. L'Aquila, Italy.
3Institut für Pharmakologie und Toxikologie, Universität Würzburg, Würzburg, Germany.
4Department of Neuroscience. University of Pisa. Pisa. Italy.
*Corresponding author: Prof. Claudia Martini. Dept of Psychiatry, Neurobiology, Pharmacology and
Biotechnology. University of Pisa. Via Bonanno, 6, 56127 Pisa. E-mail: [email protected].
Phone Number: +39.0502219522; FAX number: +39.0502219609.
A
Fig. 1
B/F
20000
10000
0
0
500
1000
1500
fmol/mg
B
400
B/F
300
200
100
0
0
1000 2000 3000 4000 5000 6000 7000
fmol/mg
Fig. 1 Scatchard Plot of (A) [3H]YM09151-2 (D2DRs) and (B) [3H]NECA (A2AARs) binding data
performed in CHO cells co-expressing both D2DRs and A2AARs. Graphs show a representative
Scatchard Plot from saturation (A) and competition (B) binding studies performed three times with
similar results.